Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of BioTelemetry, Inc. (NASDAQ:BEAT) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 7,020 shares of the medical research company’s stock, valued at approximately $232,000.

Other large investors also recently added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. acquired a new position in BioTelemetry during the 3rd quarter worth $109,000. Pinebridge Investments L.P. boosted its position in BioTelemetry by 2.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 3,775 shares of the medical research company’s stock worth $126,000 after acquiring an additional 75 shares during the period. Victory Capital Management Inc. boosted its position in BioTelemetry by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the medical research company’s stock worth $140,000 after acquiring an additional 626 shares during the period. US Bancorp DE acquired a new position in BioTelemetry during the 2nd quarter worth $145,000. Finally, State of Alaska Department of Revenue boosted its position in BioTelemetry by 80.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 5,638 shares of the medical research company’s stock worth $188,000 after acquiring an additional 2,508 shares during the period. Institutional investors and hedge funds own 82.23% of the company’s stock.

Shares of BioTelemetry, Inc. (NASDAQ:BEAT) opened at $26.85 on Tuesday. BioTelemetry, Inc. has a 12 month low of $19.95 and a 12 month high of $39.20. The company has a quick ratio of 1.48, a current ratio of 1.60 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $896.08, a price-to-earnings ratio of 37.88, a PEG ratio of 1.73 and a beta of 0.53.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Tuesday, November 7th. The medical research company reported $0.16 EPS for the quarter, missing the Zacks’ consensus estimate of $0.25 by ($0.09). BioTelemetry had a return on equity of 13.66% and a net margin of 16.10%. The firm had revenue of $81.02 million during the quarter, compared to the consensus estimate of $82.10 million. During the same period in the prior year, the firm posted $0.21 EPS. The firm’s quarterly revenue was up 52.7% on a year-over-year basis. research analysts forecast that BioTelemetry, Inc. will post 0.83 earnings per share for the current fiscal year.

A number of research analysts have issued reports on the company. Dougherty & Co reiterated a “buy” rating and set a $40.00 price target on shares of BioTelemetry in a research report on Wednesday, November 8th. Zacks Investment Research lowered BioTelemetry from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 2nd. Raymond James Financial began coverage on BioTelemetry in a research note on Thursday, October 26th. They issued an “outperform” rating and a $37.00 price objective on the stock. SunTrust Banks began coverage on BioTelemetry in a research note on Monday, October 23rd. They issued a “buy” rating and a $41.00 price objective on the stock. Finally, Off Wall Street began coverage on BioTelemetry in a research note on Friday, September 15th. They issued a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $42.86.

TRADEMARK VIOLATION NOTICE: “7,020 Shares in BioTelemetry, Inc. (BEAT) Purchased by Los Angeles Capital Management & Equity Research Inc.” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/7020-shares-in-biotelemetry-inc-beat-purchased-by-los-angeles-capital-management-equity-research-inc/1744415.html.

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.